DUBLIN, Ohio--(BUSINESS WIRE)--Neoprobe Corporation (NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced that results from a Phase II study of Lymphoseek® (Tilmanocept) have been published online in the Annals of Surgical Oncology and demonstrate the tracing agent’s ability to identify tumor-draining lymph nodes in breast cancer and melanoma patients. The publication of the multi-center clinical results was announced yesterday after market close by Dr. Stanley Leong, Chief of Cutaneous Oncology and Associate Director of the Melanoma Program at the Center for Melanoma Research and Treatment, California Pacific Medical Center. Dr. Leong was the lead author of the study.
